Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

ARNA 4.51 -0.05 (-1.10%)
price chart
Arena Pharmaceuticals (ARNA) Stock Crippled By Risk, Dilution
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock has been on quite a roller coaster ride in 2015. A few weeks ago, ARNA shares roared 76% higher in a single day after positive early-stage trials for an autoimmune disease treatment gave investors a ...
Arena Pharmaceuticals Coverage Initiated by Analysts at RBC Capital (ARNA)  sleekmoney
Market Buzz: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Arena ...  Market News Call
Why Arena Pharmaceuticals, Inc. Stock Slumped 17% in December
What: Shares of Arena Pharmaceuticals (NASDAQ: ARNA ) , a biopharmaceutical company primarily focused on developing drugs for weight control management purposes, slumped 17% in December, based on data from S&P Capital IQ, after a rival received ...
Why Shares of Arena Pharmaceuticals, Inc. Skyrocketed Today
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
ARNA Stock Pops, And There's Plenty More Where That Came From
Arena's APD334 Has Real Blockbuster Potential (ARNA)  Seeking Alpha
Update: Arena Pharmaceuticals, Inc. Short Interest Disclosure
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has shown a drop of 0.7% or 267,429 shares in the short positions. The bets have increased to 37,730,047 shares on January 15,2015 from 37,997,476 shares on December 31,2014.
Morning Stock Trends: NRG Energy, Inc. (NRG), Arena Pharmaceuticals, Inc ...  WallStreet Scope
Arena Pharmaceuticals, Inc. Analyst Rating Update
Research firm Zacks has rated Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and has ranked it at 3, indicating that its shares are a Neutral.
Trade-Ideas: Arena Pharmaceuticals (ARNA) Is Today's Pre-Market Leader Stock
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Belviq IMS Gains Consistent With Symphony (ARNA)
Belviq retains 40% share compared to Qsymia and Contrave, although both post better than expected numbers. Due to discounting, Arena guided to 35-45% less revenue for Q4. Whether that may be recouped in Q1 2015 may be determined by Contrave's ...
Arena Pharmaceuticals (ARNA) Showing Signs Of A Dead Cat Bounce Today
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Related articles »  
Arena's Sales Pace For Belviq - What Is Needed (ARNA)
With Eisai and Arena Pharmaceuticals (NASDAQ:ARNA) announcing new and less expensive pricing for Belviq, investors will want to be keen on the new dynamics that such an action presents.
Arena (ARNA) Predicts Lower BELVIQ Revenue In Fourth Quarter Of 2014  Bidness ETC
Eisai Launches New Savings Card to Increase Access and Affordability of ...  Pharmacy Times
Short Interest of Arena Pharmaceuticals, Inc. Drops
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has witnessed a colossal drop of 2.4% or 923,609 shares in its short figure.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Initiates Phase 2 Clinical Trials  Inside Trade
Arena Pharmaceuticals Doses for Cardiovascular Study